Dr. Reddys, Novartis settle over Exelon patent litigation

HYDERABAD, India Dr. Reddy’s and Novartis have settled a patent litigation suit in regards to rivastigmine tartrate, a generic version of the Alzheimer’s drug Exelon, according to published reports.

Under the terms of the agreement, Dr Reddy’s won’t launch its generic rivastigmine tartrate capsules until sometime before the expiration of the Exelon patents, which start to expire in 2012.

The launch date was not released by either company. According to IMS data, annual sales of Exelon in the U.S. is about $200 million.